- English (UK)
- English (India)
- English (Canada)
- English (Australia)
- English (South Africa)
- English (Philippines)
- English (Nigeria)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Português (Portugal)
- Polski
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
Formycon AG (FYB)
Formycon AG stock price live, this page displays ETR FYB stock exchange data. View the FYB premarket stock price ahead of the market session or assess the after hours quote. Monitor the latest movements within the Formycon AG real time stock price chart below.
What Is the Formycon AG Stock Price Today?
The Formycon AG stock price today is 24.35.
What Is the Stock Symbol for Formycon AG?
The stock ticker symbol for Formycon AG is FYB.
Is FYB the Same as $FYB?
$FYB is a common way to refer to the Formycon AG ticker symbol in social media, forums, and online discussions. The dollar sign is a shorthand convention used to indicate that it is a stock ticker symbol
What Stock Exchange Does Formycon AG Trade On?
Formycon AG is listed and trades on the Xetra stock exchange.
Is Formycon AG a Good Stock to Buy?
Determining whether Formycon AG—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess the current Formycon AG share price compared with the fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the FYB quote. (ISIN: DE000A1EWVY8)
What Is the Formycon AG Stock Price Today?
The Formycon AG stock price today is 24.35.
What Is the Stock Symbol for Formycon AG?
The stock ticker symbol for Formycon AG is FYB.
Is FYB the Same as $FYB?
$FYB is a common way to refer to the Formycon AG ticker symbol in social media, forums, and online discussions. The dollar sign is a shorthand convention used to indicate that it is a stock ticker symbol
What Stock Exchange Does Formycon AG Trade On?
Formycon AG is listed and trades on the Xetra stock exchange.
Is Formycon AG a Good Stock to Buy?
Determining whether Formycon AG—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess the current Formycon AG share price compared with the fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the FYB quote. (ISIN: DE000A1EWVY8)
24.05
-0.25(-1.03%)
Delayed Data·
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
23.90
24.80
52 wk Range
19.18
64.40
FYB Scorecard
Full Analysis
Analysts anticipate sales decline in the current year
FYB is not included in our AI-picked strategies. See which stocks are.
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
23.9024.80
52 wk Range
19.1864.40
Key Statistics
Edit
Prev. Close
Open
Volume
Average Vol. (3m)
1-Year Change
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Book Value / Share
Prev. Close
Open
Volume
Average Vol. (3m)
1-Year Change
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Book Value / Share
FYB Scorecard
Company’s Health
Assesses a company's financial position by analyzing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PricePrice Target
49.33
Upside
+105.13%
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
Analysts do not anticipate the company will be profitable this year
Formycon AG Company Profile
Formycon AG, a biotechnology company, develops biosimilar drugs in Germany and Switzerland. It provides ranibizumab and aflibercept used in the treatment of neovascular age-related macular degeneration, diabetic macular edema, choroidal neovascularization, proliferative diabetic retinopathy, and macular edema under the Ranivisio, Ongavia, Cimerli, Ranopto, Uptera, and Ravegza brand names, as well as AHZANTIVE, Baiama, and Fovlya brand names. The company’s pipeline includes ustekinumab used in the treatment of Crohn’s disease, ulcerative colitis, Plaque Psoriasis, and Psoriatic Arthritis under the Otulf, Fymskina, and Sitovab brand names. It is also developing pembrolizumab for the treatment of immuno-oncology diseases, such as advanced melanoma, non-small cell bronchial carcinoma, hodgkin’s lymphoma, urothelial carcinomas, tumors in the head and neck area, other tumor diseases; and FYB208 and FYB209 that is indicated for immunology areas. The company was formerly known as Nanohale AG and changed its name to Formycon AG in 2012. Formycon AG was founded in 1999 and is headquartered in Planegg, Germany.
Formycon AG Earnings Call Summary for Q1/2025
- Q1 2025 revenue fell to €5.3M from €17.7M YoY; stock price dropped 3.08% to €24.35
- Full-year revenue guidance of €55-60M, with significant growth expected in Q3 and Q4 2025
- Strong cash position of €33M and equity ratio of 58%; company targets EBITDA profitability by next year
- Focus on biosimilars pipeline and strategic partnerships; approvals for FIB22 Otafi in Canada and UK
- Analysts maintain 'Buy' recommendation despite near-term challenges; stock appears undervalued per InvestingPro analysis
Last Updated: 05/12/2025, 09:57 AM
Read Full TranscriptCompare FYB to Peers and Sector
Metrics to compare | FYB | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipFYBPeersSector | |
|---|---|---|---|---|
P/E Ratio | −3.4x | −0.1x | −0.5x | |
PEG Ratio | 0.01 | 0.15 | 0.00 | |
Price / Book | 0.9x | 1.0x | 2.6x | |
Price / LTM Sales | 6.2x | 4.3x | 2.9x | |
Upside (Analyst Target) | 98.3% | 230.3% | 53.0% | |
Fair Value Upside | Unlock | 7.6% | 8.9% | Unlock |
Analyst Ratings
8 Buy
1 Hold
0 Sell
Ratings:
9 analysts
Overall Consensus
Buy
Analysts 12-Month Price Target:
Average 49.33
(+105.13% Upside)
Earnings
Latest Release
May 12, 2025
EPS / Forecast
0.02 / -0.04
Revenue / Forecast
9.65M / 16.00M
FAQ
What Is the Formycon (FYB) Stock Price Today?
The Formycon stock price today is 24.05
What Stock Exchange Does Formycon Trade On?
Formycon is listed and trades on the Frankfurt Stock Exchange stock exchange.
What Is the Stock Symbol for Formycon?
The stock symbol for Formycon is "FYB."
What Is the Formycon Market Cap?
As of today, Formycon market cap is 428.18M.
What Is Formycon's Earnings Per Share (TTM)?
The Formycon EPS (TTM) is -7.18.
When Is the Next Formycon Earnings Date?
Formycon will release its next earnings report on May 15, 2025.
From a Technical Analysis Perspective, Is FYB a Buy or Sell?
Based on moving averages and other technical indicators, the daily buy/sell signal is Buy.
Install Our App
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2025 - Fusion Media Limited. All Rights Reserved.